Neeraj Gupta

Publication Activity (10 Years)

Years Active: 2017-2024
Publications (10 Years): 48

Top Topics

Multiple Myeloma

Decision Making

Tyrosine Kinase

Top Venues

CPT: pharmacometrics & systems pharmacology

Clinical pharmacology and therapeutics

Investigational new drugs

Clinical and translational science

This page only lists publications with an associated author ORCID identifier.

Publications

Yuki Otani, Yunqi Zhao, Guanyu Wang, Richard Labotka, Mark Rogge, Neeraj Gupta, Majid Vakilynejad, Dean Bottino, Yusuke Tanigawara
Modeling serum M-protein response for early detection of biochemical relapse in myeloma patients treated with bortezomib, lenalidomide and dexamethasone. CPT: pharmacometrics & systems pharmacology (2024)
Michael J Hanley, Steven Zhang, Robert J Griffin, Sean Xiaochun Zhu, Robert J Fram, Jianchang Lin, Karthik Venkatakrishnan, Neeraj Gupta
A phase 1 study to assess the absolute bioavailability, mass balance, pharmacokinetics, metabolism, and excretion of [ 14 C]-mobocertinib, an oral inhibitor of EGFR exon 20 insertion mutations, in healthy participants. Investigational new drugs 42 (4) (2024)
Michael J Hanley, D Ross Camidge, Robert J Fram, Neeraj Gupta
Mobocertinib: Mechanism of action, clinical, and translational science. Clinical and translational science 17 (3) (2024)
Divya Samineni, Karthik Venkatakrishnan, Ahmed A Othman, Yazdi K Pithavala, Srinivasu Poondru, Chirag Patel, Pavan Vaddady, Wendy Ankrom, Saroja Ramanujan, Nageshwar Budha, Michael Wu, Nahor Haddish-Berhane, Holger Fritsch, Azher Hussain, Jitendra Kanodia, Meng Li, Mengyao Li, Murad Melhem, Apurvasena Parikh, Vijay V Upreti, Neeraj Gupta
Dose Optimization in Oncology Drug Development: An International Consortium for Innovation and Quality in Pharmaceutical Development White Paper. Clinical pharmacology and therapeutics 116 (3) (2024)
Zeshan Hussain, Edward De Brouwer, Rebecca Boiarsky, Sama Setty, Neeraj Gupta, Guohui Liu, Cong Li, Jaydeep Srimani, Jacob Zhang, Rich Labotka, David Sontag
Joint AI-driven event prediction and longitudinal modeling in newly diagnosed and relapsed multiple myeloma. NPJ digital medicine 7 (1) (2024)
Karthik Venkatakrishnan, Priya Jayachandran, Shirley K Seo, Piet H van der Graaf, John A Wagner, Neeraj Gupta
Moving the needle for oncology dose optimization: A call for action. CPT: pharmacometrics & systems pharmacology (2024)
Michael J Hanley, Steven Zhang, Robert J Griffin, Sean Xiaochun Zhu, Robert J Fram, Jianchang Lin, Karthik Venkatakrishnan, Neeraj Gupta
A phase 1 study to assess the absolute bioavailability, mass balance, pharmacokinetics, metabolism, and excretion of [ 14 C]-mobocertinib, an oral inhibitor of EGFR exon 20 insertion mutations, in healthy participants. Investigational new drugs 42 (4) (2024)
Michael J Hanley, Karen Rowland Yeo, Meera Tugnait, Shinji Iwasaki, Narayana Narasimhan, Pingkuan Zhang, Karthik Venkatakrishnan, Neeraj Gupta
Evaluation of the drug-drug interaction potential of brigatinib using a physiologically-based pharmacokinetic modeling approach. CPT: pharmacometrics & systems pharmacology 13 (4) (2024)
Michael J Hanley, Karen Rowland Yeo, Meera Tugnait, Shinji Iwasaki, Narayana Narasimhan, Pingkuan Zhang, Karthik Venkatakrishnan, Neeraj Gupta
Evaluation of the drug-drug interaction potential of brigatinib using a physiologically-based pharmacokinetic modeling approach. CPT: pharmacometrics & systems pharmacology 13 (4) (2024)
Zeshan Hussain, Edward De Brouwer, Rebecca Boiarsky, Sama Setty, Neeraj Gupta, Guohui Liu, Cong Li, Jaydeep Srimani, Jacob Zhang, Rich Labotka, David Sontag
Joint AI-driven event prediction and longitudinal modeling in newly diagnosed and relapsed multiple myeloma. NPJ digital medicine 7 (1) (2024)
Michael J Hanley, Karen Rowland Yeo, Meera Tugnait, Shinji Iwasaki, Narayana Narasimhan, Pingkuan Zhang, Karthik Venkatakrishnan, Neeraj Gupta
Evaluation of the drug-drug interaction potential of brigatinib using a physiologically-based pharmacokinetic modeling approach. CPT: pharmacometrics & systems pharmacology (2024)
Karthik Venkatakrishnan, Priya Jayachandran, Shirley K Seo, Piet H van der Graaf, John A Wagner, Neeraj Gupta
Moving the needle for oncology dose optimization: A call for action. Clinical and translational science 17 (6) (2024)
Michael J Hanley, Karen Rowland Yeo, Meera Tugnait, Shinji Iwasaki, Narayana Narasimhan, Pingkuan Zhang, Karthik Venkatakrishnan, Neeraj Gupta
Evaluation of the drug-drug interaction potential of brigatinib using a physiologically-based pharmacokinetic modeling approach. CPT: pharmacometrics & systems pharmacology 13 (4) (2024)
Karthik Venkatakrishnan, Priya Jayachandran, Shirley K Seo, Piet H van der Graaf, John A Wagner, Neeraj Gupta
Moving the needle for oncology dose optimization: A call for action. CPT: pharmacometrics & systems pharmacology 13 (6) (2024)
Michael J Hanley, D Ross Camidge, Robert J Fram, Neeraj Gupta
Mobocertinib: Mechanism of action, clinical, and translational science. Clinical and translational science 17 (3) (2024)
Karthik Venkatakrishnan, Priya Jayachandran, Shirley K Seo, Piet H van der Graaf, John A Wagner, Neeraj Gupta
Moving the needle for oncology dose optimization: A call for action. CPT: pharmacometrics & systems pharmacology 13 (6) (2024)
Michael J Hanley, Steven Zhang, Robert J Griffin, Sean Xiaochun Zhu, Robert J Fram, Jianchang Lin, Karthik Venkatakrishnan, Neeraj Gupta
A phase 1 study to assess the absolute bioavailability, mass balance, pharmacokinetics, metabolism, and excretion of [ 14 C]-mobocertinib, an oral inhibitor of EGFR exon 20 insertion mutations, in healthy participants. Investigational new drugs 42 (4) (2024)
Michael J Hanley, D Ross Camidge, Robert J Fram, Neeraj Gupta
Mobocertinib: Mechanism of action, clinical, and translational science. Clinical and translational science 17 (3) (2024)
Michael J Hanley, Karen Rowland Yeo, Meera Tugnait, Shinji Iwasaki, Narayana Narasimhan, Pingkuan Zhang, Karthik Venkatakrishnan, Neeraj Gupta
Evaluation of the drug-drug interaction potential of brigatinib using a physiologically-based pharmacokinetic modeling approach. CPT: pharmacometrics & systems pharmacology (2024)
Michael J Hanley, Karen Rowland Yeo, Meera Tugnait, Shinji Iwasaki, Narayana Narasimhan, Pingkuan Zhang, Karthik Venkatakrishnan, Neeraj Gupta
Evaluation of the drug-drug interaction potential of brigatinib using a physiologically-based pharmacokinetic modeling approach. CPT: pharmacometrics & systems pharmacology 13 (4) (2024)
Karthik Venkatakrishnan, Priya Jayachandran, Shirley K Seo, Piet H van der Graaf, John A Wagner, Neeraj Gupta
Moving the needle for oncology dose optimization: A call for action. Clinical and translational science 17 (6) (2024)
Zeshan Hussain, Edward De Brouwer, Rebecca Boiarsky, Sama Setty, Neeraj Gupta, Guohui Liu, Cong Li, Jaydeep Srimani, Jacob Zhang, Rich Labotka, David Sontag
Joint AI-driven event prediction and longitudinal modeling in newly diagnosed and relapsed multiple myeloma. NPJ digital medicine 7 (1) (2024)
Michael J Hanley, Steven Zhang, Robert J Griffin, Sean Xiaochun Zhu, Robert J Fram, Jianchang Lin, Karthik Venkatakrishnan, Neeraj Gupta
A phase 1 study to assess the absolute bioavailability, mass balance, pharmacokinetics, metabolism, and excretion of [ 14 C]-mobocertinib, an oral inhibitor of EGFR exon 20 insertion mutations, in healthy participants. Investigational new drugs (2024)
Divya Samineni, Karthik Venkatakrishnan, Ahmed A Othman, Yazdi K Pithavala, Srinivasu Poondru, Chirag Patel, Pavan Vaddady, Wendy Ankrom, Saroja Ramanujan, Nageshwar Budha, Michael Wu, Nahor Haddish-Berhane, Holger Fritsch, Azher Hussain, Jitendra Kanodia, Meng Li, Mengyao Li, Murad Melhem, Apurvasena Parikh, Vijay V Upreti, Neeraj Gupta
Dose Optimization in Oncology Drug Development: An International Consortium for Innovation and Quality in Pharmaceutical Development White Paper. Clinical pharmacology and therapeutics (2024)
Karthik Venkatakrishnan, Priya Jayachandran, Shirley K Seo, Piet H van der Graaf, John A Wagner, Neeraj Gupta
Moving the Needle for Oncology Dose Optimization: A Call for Action. Clinical pharmacology and therapeutics 115 (6) (2024)
Michael J Hanley, Karen Rowland Yeo, Meera Tugnait, Shinji Iwasaki, Narayana Narasimhan, Pingkuan Zhang, Karthik Venkatakrishnan, Neeraj Gupta
Evaluation of the drug-drug interaction potential of brigatinib using a physiologically-based pharmacokinetic modeling approach. CPT: pharmacometrics & systems pharmacology 13 (4) (2024)
Karthik Venkatakrishnan, Priya Jayachandran, Shirley K Seo, Piet H van der Graaf, John A Wagner, Neeraj Gupta
Moving the needle for oncology dose optimization: A call for action. CPT: pharmacometrics & systems pharmacology 13 (6) (2024)
Jaydeep K Srimani, Paul Matthias Diderichsen, Michael J Hanley, Richard Labotka, Neeraj Gupta
Dose Titration of Ixazomib Maintenance Therapy in Transplant-Ineligible Multiple Myeloma: Exposure-Response Analysis of the TOURMALINE-MM4 Study. Clinical pharmacology and therapeutics (2023)
Jackson Burton, Bilal Abuasal, Sagar Bachhav, Jamie Connarn, Josh Cosman, Neeraj Gupta, Jing Jing, Sarah Kim, Tao Long, Nadia Terranova, Karthik Venkatakrishnan, Jian Wang, Qi Liu
Future Opportunities in Drug Development: American Society for Clinical Pharmacology and Therapeutics Pharmacometrics and Pharmacokinetics Community Vision. Clinical pharmacology and therapeutics (2023)
Michael J Hanley, Paul Matthias Diderichsen, Benjamin Rich, Anna Largajolli, Emilie Schindler, Alexander Vorog, Karthik Venkatakrishnan, Neeraj Gupta
Response-Based Dosing for Ponatinib: Model-Based Analyses of the Dose-Ranging OPTIC Study. Clinical pharmacology and therapeutics (2023)
Neeraj Gupta, Michael J Hanley, Robert J Griffin, Pingkuan Zhang, Karthik Venkatakrishnan, Vikram Sinha
Clinical Pharmacology of Brigatinib: A Next-Generation Anaplastic Lymphoma Kinase Inhibitor. Clinical pharmacokinetics (2023)
Michael J Hanley, David Kerstein, Meera Tugnait, Narayana Narasimhan, Thomas C Marbury, Karthik Venkatakrishnan, Neeraj Gupta
Brigatinib pharmacokinetics in patients with chronic hepatic impairment. Investigational new drugs (2023)
Jaydeep K Srimani, Paul M Diderichsen, Michael J Hanley, Karthik Venkatakrishnan, Richard Labotka, Neeraj Gupta
Population pharmacokinetic/pharmacodynamic joint modeling of ixazomib efficacy and safety using data from the pivotal phase III TOURMALINE-MM1 study in multiple myeloma patients. CPT: pharmacometrics & systems pharmacology 11 (8) (2022)
Neeraj Gupta, Karen L Reckamp, David R Camidge, Huub J Kleijn, Aziz Ouerdani, Francesco Bellanti, John Maringwa, Michael J Hanley, Shining Wang, Pingkuan Zhang, Karthik Venkatakrishnan
Population pharmacokinetic and exposure-response analyses from ALTA-1L: Model-based analyses supporting the brigatinib dose in ALK-positive NSCLC. Clinical and translational science 15 (5) (2022)
Michael J Hanley, Manolo D'Arcangelo, Enriqueta Felip, Pilar Garrido, Jiaxi Zhu, Meng Ye, Florin Vranceanu, Neeraj Gupta
A Phase 1 Drug-Drug Interaction Study Between Brigatinib and the CYP3A Substrate Midazolam in Patients With ALK-Positive or ROS1-Positive Solid Tumors. Journal of clinical pharmacology (2022)
Neeraj Gupta, Philippe B Pierrillas, Michael J Hanley, Steven Zhang, Paul Matthias Diderichsen
Population pharmacokinetics of mobocertinib in healthy volunteers and patients with non-small cell lung cancer. CPT: pharmacometrics & systems pharmacology 11 (6) (2022)
Neeraj Gupta, Michael J Hanley, Vikram Sinha
Pharmacometric analyses and clinical evidence for brigatinib dosing in anaplastic lymphoma kinase-positive non-small cell lung cancer. British journal of clinical pharmacology 88 (8) (2022)
Karthik Venkatakrishnan, Neeraj Gupta, Patrick F Smith, Tiffany Lin, Neil Lineberry, Tatiana Ishida, Lin Wang, Mark Rogge
Asia-Inclusive Clinical Research and Development Enabled by Translational Science and Quantitative Clinical Pharmacology: Toward a Culture That Challenges the Status Quo. Clinical pharmacology and therapeutics (2022)
Neeraj Gupta, Michael J Hanley, David Kerstein, Meera Tugnait, Narayana Narasimhan, Thomas C Marbury, Karthik Venkatakrishnan
Effect of severe renal impairment on the pharmacokinetics of brigatinib. Investigational new drugs 39 (5) (2021)
Toshio Shimizu, Yasutoshi Kuboki, Chia-Chi Lin, Kan Yonemori, Tomoko Yanai, Douglas V Faller, Lwona Dobler, Neeraj Gupta, Farhad Sedarati, Kyu-Pyo Kim
A Phase 1 Study of Sapanisertib (TAK-228) in East Asian Patients with Advanced Nonhematological Malignancies. Targeted oncology (2021)
Neeraj Gupta, Xiaohui Wang, Elliot Offman, Marita Prohn, Narayana Narasimhan, David Kerstein, Michael J Hanley, Karthik Venkatakrishnan
Population Pharmacokinetics of Brigatinib in Healthy Volunteers and Patients With Cancer. Clinical pharmacokinetics 60 (2) (2021)
Neeraj Gupta, Michael J Hanley, Cindy Xia, Richard Labotka, R Donald Harvey, Karthik Venkatakrishnan
Clinical Pharmacology of Ixazomib: The First Oral Proteasome Inhibitor. Clinical pharmacokinetics 58 (4) (2020)
Neeraj Gupta, Dean Bottino, Ulrika S H Simonsson, Cynthia J Musante, Tjerk Bueters, Theodore R Rieger, Sreeraj Macha, Marylore Chenel, Craig Fancourt, Jitendra Kanodia, Satyaprakash Nayak
Transforming Translation Through Quantitative Pharmacology for High-Impact Decision Making in Drug Discovery and Development. Clinical pharmacology and therapeutics 107 (6) (2019)
Neeraj Gupta, Huyuan Yang, Michael J Hanley, Steven Zhang, Rachael Liu, Shaji Kumar, Paul G Richardson, Tomas Skacel, Karthik Venkatakrishnan
Dose and Schedule Selection of the Oral Proteasome Inhibitor Ixazomib in Relapsed/Refractory Multiple Myeloma: Clinical and Model-Based Analyses. Targeted oncology 12 (5) (2018)
Paul Gerard Richardson, Craig C Hofmeister, Cara A Rosenbaum, Myo Htut, David H Vesole, Jesus G Berdeja, Michaela Liedtke, Ajai Chari, Stephen D Smith, Daniel Lebovic, Noopur Raje, Catriona Byrne, Eileen Liao, Neeraj Gupta, Alessandra Di Bacco, Jose Estevam, Deborah Berg, Rachid Baz
Twice-weekly ixazomib in combination with lenalidomide-dexamethasone in patients with newly diagnosed multiple myeloma. British journal of haematology 182 (2) (2018)
Shaji K Kumar, Norbert Grzasko, Sosana Delimpasi, Wieslaw W Jedrzejczak, Sebastian Grosicki, Marie-Christine Kyrtsonis, Andrew Spencer, Neeraj Gupta, Zhaoyang Teng, Catriona Byrne, Richard Labotka, Meletios- Athanasios Dimopoulos
Phase 2 study of all-oral ixazomib, cyclophosphamide and low-dose dexamethasone for relapsed/refractory multiple myeloma. British journal of haematology 184 (4) (2018)
Neeraj Gupta, Steven Zhang, Sandeepraj Pusalkar, Mihaela Plesescu, Swapan Chowdhury, Michael J Hanley, Bingxia Wang, Cindy Xia, Xiaoquan Zhang, Karthik Venkatakrishnan, Dale R Shepard
A phase I study to assess the mass balance, excretion, and pharmacokinetics of [14C]-ixazomib, an oral proteasome inhibitor, in patients with advanced solid tumors. Investigational new drugs 36 (3) (2017)
Shaji K Kumar, Phillipe Moreau, Parameswaran Hari, Maria-Victoria Mateos, Heinz Ludwig, Chaim Shustik, Tamas Masszi, Andrew Spencer, Roman Hájek, Kenneth Romeril, Irit Avivi, Anna M Liberati, Monique C Minnema, Hermann Einsele, Sagar Lonial, Deborah Berg, Jianchang Lin, Neeraj Gupta, Dixie-Lee Esseltine, Paul G Richardson
Management of adverse events associated with ixazomib plus lenalidomide/dexamethasone in relapsed/refractory multiple myeloma. British journal of haematology 178 (4) (2017)